Saturday 17 October 2026
Export APLM’s income statement to Excel — free account
Apollomics Inc.
APLM Healthcare Biotechnology
Apollomics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 million, up 470.9% from fiscal 2024. Insiders bought in the last twelve months.
21.10
0.10
+0.48%
Follow APLM
Apollomics Inc. (APLM) P/E ratio
Apollomics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | n/m |
| XLO Xilio Therapeutics, Inc. compare | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| BMEA Biomea Fusion, Inc. compare | n/m |
| PLRX Pliant Therapeutics, Inc. compare | n/m |
| GANX Gain Therapeutics, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| APLM Apollomics Inc. | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)